AstraZeneca’s Imfinzi (Durvalumab) Secures the US FDA’s Approval for Treating Limited-Stage Small Cell Lung Cancer
Shots:
- The US FDA has approved Imfinzi for treating limited-stage small cell lung cancer (LS-SCLC) in adults, not progressed after concurrent Pt-based CT and radiation therapy, based on P-III (ADRIATIC) study. Submissions are under review across the EU, Japan & other regions
- The trial assessed Imfinzi (1500mg, Q4W) with/without Imjudo (75mg, Q4W) vs PBO in LS-SCLC patients (n=730)
- Study depicted reduction in the death risk by 27%, with mOS of 55.9 vs 33.4mos (57% vs 48% were alive at 3yrs.) and reduction in the risk of progression or death by 24%, with mPFS of 16.6 vs 9.2mos. (46% vs 34% remained progression free at 2yrs.)
Ref: AstraZeneca | Image: AstraZeneca
Related News:- AstraZeneca Provides Update on P-III (CAPItello-281) Study of Truqap Regimen in PTEN-Deficient mHSPC
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
